Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not a subscriber? Subscribe now for unlimited access to online articles.

Emily Singer

A View from Emily Singer

A Way to Fix Lightweight Drinkers

A compound may repair a defective enzyme in people who metabolize alcohol poorly.

  • January 11, 2010

An estimated 40 percent of people of East Asian descent carry a defective copy of a gene involved in breaking down alcohol, making them more susceptible to the harmful effects of drinking, such as nausea, facial flushing and rapid heartbeat. The gene codes for an enzyme called aldehyde dehydrogenase 2 (ALDH2), which breaks down a toxic metabolite of alcohol, acetaldehyde, into non-toxic acetate.

Researchers have now identified a molecule, called Alda-1, that appears to restore activity of the defective form of the enzyme. According to a release from the National Institute on Alcohol Abuse and Alcoholism, which funded the research:

The normal, active form of ALDH2 creates a catalytic tunnel, a space within the enzyme in which acetaldehyde is metabolized. In the defective enzyme, the tunnel does not function properly. Alda-1 binds to the defective enzyme in a way that effectively reopens the catalytic tunnel and thus allows the enzyme to metabolize acetaldehyde. Alda-1 binds to the defective enzyme in a way that effectively reopens the catalytic tunnel and thus allows the enzyme to metabolize acetaldehyde.

Research has shown that people with two defective copies of the gene are less susceptible to alcoholism. So why would you need a drug that helped them drink? Because the enzyme is also responsible for breaking down other toxic aldehydes that can accumulate in the body. The defective variation has been linked to an increased risk of cancer, and lack of response to nitroglycerin, a drug used to treat chest pain. According to Thomas Hurley, a biologist at Indiana University School of Medicine in Indianapolis who led the research, it “opens up the possibility of designing new analogs that can selectively affect the metabolism of other molecules that are detoxified by aldehyde dehydrogenase.”

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.

Subscribe today
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Print + All Access Digital.
  • Print + All Access Digital {! insider.prices.print_digital !}*

    {! insider.display.menuOptionsLabel !}

    The best of MIT Technology Review in print and online, plus unlimited access to our online archive, an ad-free web experience, discounts to MIT Technology Review events, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    6 bi-monthly issues of print + digital magazine

    10% discount to MIT Technology Review events

    Access to entire PDF magazine archive dating back to 1899

    Ad-free website experience

    The Download: newsletter delivery each weekday to your inbox

    The MIT Technology Review App

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.